The DOI matches its Crossref record; 250 of the 253 references it cites were found in a registry or an index, and 2 are not checked yet.
Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across
Open accessAbstract
The recent approval of messenger RNA (mRNA)-based vaccines to combat the SARS-CoV-2 pandemic highlights the potential of both conventional mRNA and self-amplifying mRNA (saRNA) as a flexible immunotherapy platform to treat infectious diseases. Besides the antigen it encodes, mRNA itself has an immune-stimulating activity that can contribute to vaccine efficacy. This self-adjuvant effect, however, will interfere with mRNA translation and may influence the desired therapeutic outcome. To further exploit its potential as a versatile therapeutic platform, it will be crucial to control mRNA's innate immune-stimulating properties. In this regard, we describe the mechanisms behind the innate immune recognition of mRNA and provide an extensive overview of strategies to control its innate immune-stimulating activity. These strategies range from modifications to the mRNA backbone itself, optimization of production and purification processes to the combination with innate immune inhibitors. Furthermore, we discuss the delicate balance of the self-adjuvant effect in mRNA vaccination strategies, which can be both beneficial and detrimental to the therapeutic outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the current understanding of the field is that incorporating modified NTPs into saRNA abrogates downstream efficacy, as reported by multiple independent groups5,19–28.”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“saRNAs use an RNA-dependent RNA polymerase from an alphavirus and the corresponding conserved sequence elements at the 5′ and 3′ ends for replication, leading to robust and durable expression of encoded protein cargo5–7.”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The early and intense type I IFN response induced by saRNA detection hinders replication and antigen expression, similar to unmodified mRNA5,13–15.”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Aviv, H., & Leder, P. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.6.1408 · Cited by 6,636
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature reviews. Immunology · doi:10.1038/nri1604 · Cited by 3,631
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2013) · Nature reviews. Immunology · doi:10.1038/nri3581 · Cited by 3,442
Interferon-stimulated genes: A complex web of host defenses
Schneider, W. M., Chevillotte, M. D., & Rice, C. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120231 · Cited by 3,067
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Cited by
Sorted by citations
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Shi, Y., Shi, M., Wáng, Y., & You, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02002-z · Cited by 243
Chemically Modified Platforms for Better RNA Therapeutics
Shi, Y., Zhen, X., Zhang, Y., Li, Y., Koo, S., Saiding, Q., Kong, N., Liu, G., Chen, W., & Tao, W. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00611 · Cited by 189
Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines
Kim, B., Hosn, R. R., Remba, T. K., Yun, D. S., Li, N., Abraham, W. D., Melo, M. B., Cortés, M., Li, B., Zhang, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.022 · Cited by 157
mRNA in the Context of Protein Replacement Therapy
Vavilis, T., Stamoula, Ε., Ainatzoglou, A., Sachinidis, A., Lamprinou, M., Dardalas, I., & Vizirianakis, I. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010166 · Cited by 145
Zhang, H., Vandesompele, J., Braeckmans, K., Smedt, S. C. D., & Remaut, K. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00194f · Cited by 146
Self-citationAmplifying gene expression with RNA-targeted therapeutics
Khorkova, O., Stahl, J., Joji, A., Volmar, C., & Wahlestedt, C. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00704-7 · Cited by 136
Quality by Design for enabling RNA platform production processes
Daniel, S., Kis, Z., Kontoravdi, C., & Shah, N. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.03.012 · Cited by 129
Yang, J., Tseng, J., Yu, G., Luo, Y., Huang, C. F., Hong, Y., & Chuang, T. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020423 · Cited by 129
The advent of clinical self-amplifying RNA vaccines
Casmil, I. C., Jin, J., Won, E.-J., Huang, C., Liao, S., Cha‐Molstad, H., & Blakney, A. K. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.060 · Cited by 111
Frameworks for transformational breakthroughs in RNA-based medicines
Androsavich, J. R. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00943-2 · Cited by 100
RNA chemistry and therapeutics
Wang, S., Weissman, D., & Dong, Y. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01237-x · Cited by 109
Intracellular Protein Delivery: Approaches, Challenges, and Clinical Applications
Chan, A., & Tsourkas, A. (2023) · BME Frontiers · doi:10.34133/bmef.0035 · Cited by 93
McGee, J. E., Kirsch, J. R., Kenney, D., Cerbo, F., Chavez, E. C., Shih, T.-Y., Douam, F., Wong, W. W., & Grinstaff, M. W. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02306-z · Cited by 87
“Preclinical and clinical data confirm that the early and intense IFN response inhibits antigen expression and induces inflammation 5,13,14,35 .”
BackgroundInfluentialmRNA Vaccine Development for Emerging Animal and Zoonotic Diseases
Le, T., Sun, C., Chang, J., Zhang, G., & Yin, X. (2022) · Viruses · doi:10.3390/v14020401 · Cited by 99
Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development
Schmidt, C., & Schnierle, B. S. (2023) · Pathogens · doi:10.3390/pathogens12010138 · Cited by 78
Self-Amplifying RNA Approach for Protein Replacement Therapy
Papukashvili, D., Rcheulishvili, N., Liu, C., Ji, Y., He, Y., & Wang, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112884 · Cited by 76
mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
Ouranidis, A., Vavilis, T., Mandala, E., Davidopoulou, C., Stamoula, Ε., Markopoulou, C. K., Karagianni, A., & Kachrimanis, K. (2021) · Biomedicines · doi:10.3390/biomedicines10010050 · Cited by 75
Self-Amplifying RNA: Advantages and Challenges of a Versatile Platform for Vaccine Development
Vallet, T., & Vignuzzi, M. (2025) · Viruses · doi:10.3390/v17040566 · Cited by 78
A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs
Bogaert, B., Sauvage, F., Guagliardo, R., Muntean, C., Nguyen, V. P., Pottie, E., Wels, M., Minnaert, A., Rycke, R. M. D., Yang, Q., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.009 · Cited by 69
Self-citationmRNA: A promising platform for cancer immunotherapy
Kong, B., Kim, Y., Kim, E. H., Suk, J. S., & Yang, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114993 · Cited by 74
Delivery of mRNA for regulating functions of immune cells
Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 62
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications
Yan, Y., Liu, S., Wen, J., He, Y., Duan, C., Nabavi, N., Ashrafizadeh, M., Sethi, G., Liu, L., & Ma, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02463-y · Cited by 71
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57
Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
Wang, Y., Zhang, R., Tang, L., & Li, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030512 · Cited by 58
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
Yuan, Y., Gao, F., Chang, Y., Zhao, Q., & He, X. (2023) · Biomarker Research · doi:10.1186/s40364-023-00449-w · Cited by 60
Self-amplifying mRNA vaccines: Mode of action, design, development and optimization
Pourseif, M. M., Masoudi‐Sobhanzadeh, Y., Azari, E., Parvizpour, S., Barar, J., Ansari, R. A., & Omidi, Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103341 · Cited by 57
BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
Huang, S., Pan, C., Lin, Y., Chen, M., Chen, Y., Jan, C., Wu, C., Lin, F., Wang, S. Y., Lin, C., et al. (2023) · Advanced Science · doi:10.1002/advs.202206856 · Cited by 55
Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines
Tregoning, J. S., Stirling, D. C., Wang, Z., Flight, K. E., Brown, J. C., Blakney, A. K., McKay, P. F., Cunliffe, R. F., Murugaiah, V., Fox, C. B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.11.024 · Cited by 57
Li, Y., Tian, Y., Li, C., Fang, W., Li, X., Jing, Z., Yang, Z., Zhang, X., Huang, Y., Gong, J., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102518 · Cited by 57
Kimura, T., Leal, J. M., Simpson, A., Warner, N. L., Berube, B. J., Archer, J. F., Park, S., Kurtz, R., Hinkley, T., Nicholes, K., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.017 · Cited by 52
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51
Self-citationThe Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics
Muslimov, A. R., Tereshchenko, V., Shevyrev, D., Rogova, A. S., Lepik, K. V., Reshetnikov, V. V., & Ivanov, R. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914820 · Cited by 51
Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 53
Eftekhari, Z., Zohrabi, H., Oghalaie, A., Ebrahimi, T., Shariati, F. S., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102313 · Cited by 46
Advances and applications of RNA vaccines in tumor treatment
Yang, R., & Cui, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02141-5 · Cited by 48
Palmer, C. D., Scallan, C. D., Kraemer Tardif, L. D., Kachura, M. A., Rappaport, A. R., Koralek, D. O., Uriel, A., Gitlin, L., Klein, J., Davis, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39053-9 · Cited by 42
Bathula, N. V., Friesen, J. J., Casmil, I. C., Wayne, C. J., Liao, S., Soriano, S. K. V., Ho, C.-H., Strumpel, A., & Blakney, A. K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.078 · Cited by 44
Synthetic mRNA – emerging new class of drug for tissue regeneration
Balmayor, E. R. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.10.015 · Cited by 36
Popova, P. G., Lagace, M. A., Tang, G., & Blakney, A. K. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114247 · Cited by 33
SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells
Stevenson, E. M., Terry, S. N., Copertino, D. C., Leyre, L., Danesh, A., Weiler, J., Ward, A. R., Khadka, P., McNeil, E. P., Bernard, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32376-z · Cited by 34
Path towards mRNA delivery for cancer immunotherapy from bench to bedside
Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 33
Lombaerde, E. D., Cui, X., Chen, Y., Zhong, Z., Deckers, J., Mencarelli, G., Opsomer, L., Wang, H., Baere, J. D., Lienenklaus, S., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c09677 · Cited by 31
Self-citationEngineering challenges and translational opportunities in emerging gene delivery platforms
Ma, Y., Dong, S., Wu, A., Jeong, S. D., Lee, A. S., Jiang, W., & Kim, B. Y. S. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01643-5 · Cited by 36
Schmidt, C., Haefner, E. S., Gerbeth, J., Beißert, T., Şahin, U., Perković, M., & Schnierle, B. S. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.036 · Cited by 28
Feng, S., Rcheulishvili, N., Jiang, X., Zhu, P., Pan, X., Wei, M., Wang, P. G., Ji, Y., & Papukashvili, D. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.87741 · Cited by 27
Advancing mRNA technologies for therapies and vaccines: An African context
Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P., & Bloom, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018961 · Cited by 25
“Post-transcriptional purification of synthetic mRNAs is necessary to remove immunogenic dsDNA templates and dsRNA by-products, aborted transcripts, excess reagents, and other chemical by-products to obtain full-length mRNA transcripts which would then be acceptable as pharmaceutical grade therapeutics and vaccines (re…”
BackgroundGong, N., Kim, D., Alameh, M., El-Mayta, R. D., Han, E. L., Dwivedi, G., Palanki, R., Shi, Q., Han, X., Xue, L., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01422-8 · Cited by 34
Coroadinha, A. S. (2023) · Cells · doi:10.3390/cells12050732 · Cited by 26
İmani, S., Tagit, O., & Pichon, C. (2024) · npj Vaccines · doi:10.1038/s41541-024-00807-1 · Cited by 25
RetractedRNA therapies for CNS diseases
Francesco, V. D., Chua, A. J. K., Huang, D., D’souza, A. A., Yang, A., Bleier, B. S., & Amiji, M. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115283 · Cited by 27
Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems
Nasr, S. S., Lee, S., Thiyagarajan, D., Boese, A. S., Loretz, B., & Lehr, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111924 · Cited by 22
mRNA medicine: Recent progresses in chemical modification, design, and engineering
Hou, X., Shi, J., & Xiao, Y. (2024) · Nano Research · doi:10.1007/s12274-024-6978-6 · Cited by 24
The clinical progress and challenges of mRNA vaccines
Yu, M., Wang, N., Zhu, J., & Lin, Y. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1894 · Cited by 23
Schmidt, C., Hastert, F. D., Gerbeth, J., Beißert, T., Şahin, U., Perković, M., & Schnierle, B. S. (2022) · Vaccines · doi:10.3390/vaccines10091374 · Cited by 20
Li, W., Vanluchene, H., Raes, L., Peynshaert, K., Veys, L., Hernández, S. G., Lombaerde, E. D., Geest, B. G. D., Sanders, N. N., Moons, L., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114027 · Cited by 19
Self-citationRNA Combined with Nanoformulation to Advance Therapeutic Technologies
Lima, E. S., dos Santos, D., Souza, A. L., de Macedo, M. E. O., Bandeira, M. E., Silva, S. S., Fiuza, B. S. D., Rocha, V. P. C., Fonseca, L. M. D. S., Nunes, D. D. G., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16121634 · Cited by 19
Vanluchene, H., Gillon, O., Peynshaert, K., Smedt, S. C. D., Sanders, N. N., Raemdonck, K., & Remaut, K. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114204 · Cited by 19
Self-citationDonahue, D. A., Ballesteros, C., Maruggi, G., Glover, C., Ringenberg, M. A., Marquis, M., Abdeljelil, N. B., Ashraf, A., Rodriguez, L.-A., & Stokes, A. H. (2022) · International Journal of Toxicology · doi:10.1177/10915818221138781 · Cited by 17
mRNA therapeutics for disease therapy: principles, delivery, and clinical translation
Zhou, D., Wang, K., Zhang, Y., Ma, K., Yang, X., Li, Z.-Y., Yu, S., Chen, K., & Qiao, S. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02782h · Cited by 18
Lin, G., Tang, Y., Fu, Z., Chen, R., Liu, Y., Liu, Z., Kuang, X., Sun, J., Zhao, J., & Zhang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.003 · Cited by 16
Grudzinska‐Goebel, J., Braun, M., Chen, L., Gupta, S., Lohmann, S., Morais, P., Niu, T., Tarcsa, E., Tourdot, S., Youssef, A. S., et al. (2025) · Nucleic Acid Therapeutics · doi:10.1177/21593337251387423 · Cited by 17
Casmil, I. C., Friesen, J. J., Bathula, N. V., Strumpel, A., Ho, C.-H., Guez, I., Kong, K. Y. S., Varley, A., Miyake-Stoner, S. J., Aliahmad, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202508907 · Cited by 17
Considerations on the Design of Lipid-based mRNA Vaccines Against Cancer
Meulewaeter, S., Zhang, Y., Wadhwa, A., Fox, K., Lentacker, I., Harder, K. W., Cullis, P. R., Smedt, S. C. D., Cheng, M. H. Y., & Verbeke, R. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168385 · Cited by 13
Self-citationAlam, W., Tahir, M., Hussain, S., Gul, S., Hayat, M., Irshad, R. R., & Pallonetto, F. (2024) · IEEE Access · doi:10.1109/access.2024.3352823 · Cited by 13
Delehedde, C., Ciganek, I., Rameix, N., Laroui, N., Gonçalves, C., Even, L., Midoux, P., & Pichon, C. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123531 · Cited by 14
Kunyk, D., Plotnikova, M. A., Bespalov, M., Shevyrev, D., Klotchenko, S. A., Ivanov, R. A., & Reshetnikov, V. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188986 · Cited by 17
Peña, A. C. D., Li, N., Vaduva, M., Bwanali, L., & Tripathi, A. (2023) · The Analyst · doi:10.1039/d3an00281k · Cited by 12
Non-viral delivery of RNA for therapeutic T cell engineering
Berdecka, D., Smedt, S. C. D., Vos, W. H. D., & Braeckmans, K. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115215 · Cited by 14
Wojcechowskyj, J. A., Jong, R. M., Mäger, I., Flach, B., Munson, P. V., Mukherjee, P. P., Mertins, B., Barcay, K. R., & Folliard, T. (2025) · npj Vaccines · doi:10.1038/s41541-025-01135-8 · Cited by 14
McKay, P. F., Zhou, J., Frise, R., Blakney, A. K., Bouton, C. R., Wang, Z., Hu, K., Samnuan, K., Brown, J. C., Kugathasan, R., et al. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac004 · Cited by 13
Ugwu, O. P.-C., Okon, M. B., Ogenyi, F. C., Ugwu, J. N., & Ugwu, C. N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1758902 · Cited by 10
The dawn of a new Era: mRNA vaccines in colorectal cancer immunotherapy
Song, J., Zhang, Y., Zhou, C., Zhan, J., Cheng, X., Huang, H., Mao, S., & Zong, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112037 · Cited by 10
Okada, Y., Kumagai, Y., Okura, I., Otsuki, M., Ishida, N., Iwama, Y., Minamida, T., Yagi, Y., Kurosawa, T., van Boxmeer, J., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00565-6 · Cited by 10
Chen, F., Ren, S., Huang, L., Wu, Q., Li, M., Li, S., Gao, J., Lai, Y., Cai, Z., Liu, X., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06028 · Cited by 9
Razzak, A., Ahmed, F., & Mahmud, M. T. (2025) · Scientific Reports · doi:10.1038/s41598-025-99512-9 · Cited by 9
The Road Ahead in Pancreatic Cancer: Emerging Trends and Therapeutic Prospects
Do, C. T. P., Prochnau, J. Y., Domínguez, A. M., Wang, P., & Rao, M. K. (2024) · Biomedicines · doi:10.3390/biomedicines12091979 · Cited by 9
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer
Tang, L., Que, H., Wei, Y., Yang, T., Tong, A., & Wei, X. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01694-2 · Cited by 11
Cell-specific mRNA delivery via nanobody-functionalized lipid nanoparticles
Chen, L., der Weken, H. V., Zwaenepoel, O., Okkelman, I. A., Aelvoet, J., Denberghe, E. V., Gettemans, J., Dmitriev, R. I., Geest, B. G. D., Cox, E., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114365 · Cited by 10
Poly(beta-amino esters): applications in immunology
Bayraktutan, H., Kopiasz, R. J., Elsherbeny, A., Gurnani, P., & Alexander, C. (2025) · Chemical Science · doi:10.1039/d5sc05951h · Cited by 9
Nucleic Acids as Biotools at the Interface between Chemistry and Nanomedicine in the COVID-19 Era
Borbone, N., Piccialli, I., Falanga, A. P., Piccialli, V., Roviello, G. N., & Oliviero, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084359 · Cited by 9
Malaria vaccine approaches leveraging technologies optimized in the COVID-19 era
Kanoi, B. N., Maina, M., Likhovole, C., Kobia, F., & Gitaka, J. (2022) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2022.988665 · Cited by 11
Casmil, I. C., Huang, C., & Blakney, A. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-46314-6 · Cited by 9
Lim, T. K. Y., Ritoux, A., Paine, L. W., Ferguson, L., Abdul, T., Grundy, L. J., & Smith, E. S. J. (2025) · eLife · doi:10.7554/elife.105978.3 · Cited by 9
The Application of mRNA Technology for Vaccine Production—Current State of Knowledge
Paczkowska, A., Hoffmann, K., Andrzejczak, A., Pucek, W. F., Kopciuch, D., Bryl, W., Nowakowska, E., & Kus, K. (2025) · Vaccines · doi:10.3390/vaccines13040389 · Cited by 9
Gontu, A., Misra, S., Chothe, S. K., Ramasamy, S., Jakka, P., Byukusenge, M., LaBella, L. C., Nair, M. S., Jayarao, B. M., Archetti, M., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01166-1 · Cited by 6
Lin, G., Guo, X., Fu, Z., Liu, Z., Gu, F., Yan, H., Chen, R., Liu, Y., Kuang, X., Xu, Y., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148933 · Cited by 5
Kim, B., Hosn, R. R., Remba, T. K., Dye, J., Mak, H. H., Jeong, J. Y., Cornwall-Brady, M. R., Abraham, W. D., Maiorino, L., Melo, M. B., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.09.642244 · Cited by 5
Feng, Z., Chu, L., Li, Q., Zhou, J., Wu, P., Zhang, X., Pan, Y., Zou, J., Chen, Q., Xu, Z., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68364-w · Cited by 4
Panella, R., Zanderigo, F., Morandini, F., Federico, D., Vicentini, E., Andreetta, F., Toniolo, A., & Kauppinen, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1125654 · Cited by 4
Guterres, A., Filho, P. N. S., & Moura‐Neto, V. (2024) · Vaccines · doi:10.3390/vaccines12010061 · Cited by 4
Sun, Z. F., Liu, Y., Zhang, H., Ge, T., Pan, Y., Liu, Y., Wu, M., Shan, T., Zhu, G., Wu, Q., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.30.644708 · Cited by 4
Sakhrie, A., Kalluri, A., Helal, Z. H., Kumar, C. V., & Khan, M. I. (2025) · Vaccines · doi:10.3390/vaccines13060568 · Cited by 3
Development of mRNA Cancer Vaccines: Delivery Strategies and Immunogenicity Optimization
Ali, A. (2025) · Current Medical Science · doi:10.1007/s11596-025-00127-y · Cited by 4
Chen, H., Zhang, J., Huang, J., Wu, Z., Tang, L., Tian, Y., Gao, S., Huang, S., Cao, J., Chen, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07470-7 · Cited by 3
Singh, N. S. S., Gataa, I. S., Saleh, L. H., Ganesan, S., Kavitha, V., Maharana, L., Sharma, R., Latipova, M., Madatova, N., Jumanazarov, D., et al. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04596-6 · Cited by 4
Zhao, D., Chen, G., Wang, S., Suo, Y., Ye, Q., Xing, R., Yang, Y., Li, Z., XuelianWang, Zhou, R., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128150 · Cited by 3
Bathula, N. V., Casmil, I. C., Friesen, J. J., Yuan, E., Liao, S., Maiti, B., Liou, J., Lai, M.-J., Li, S., Chen, S., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114736 · Cited by 3
Yu, H., Yang, Y., Lin, P., Liu, C., Wen, Y., Huang, Z., Fang, Z., Hu, Z., & St, H. (2026) · Nature Communications · doi:10.1038/s41467-026-69972-2 · Cited by 3
Yadav, V., Yadav, P., Mallappa, S., & Neeli, P. (2026) · Biomedicines · doi:10.3390/biomedicines14061276 · Cited by 5
Metadata
- Authors
- Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K.
- Affiliations
- Ghent University (BE)
- Corresponding author
- Remaut, Katrien
- ORCID
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 176
- Pages
- 113900
- ISSN
- 0169-409X (ISSN-L)
- PMC
- PMC8325057
- OpenAlex
- W3187029494
- Cited by
- 157
- References
- 253
- Citations by year
- 2026: 32 · 2025: 42 · 2024: 30 · 2023: 25 · 2022: 23 · 2021: 5
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Advanced Drug Delivery Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Funders
- European Commission (HORIZON2020, 810685)
- Fonds Wetenschappelijk Onderzoek (1S28420N, 11A6320N)
- Universiteit Gent
- Vlaamse regering (BOF20/PDO/041, 11A6320N)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- mRNA therapeutics, self-amplifying mRNA, innate immunity, mRNA vaccines, mRNA translation, immunotherapy, COVID-19 vaccines
- MeSH terms
- COVID-19, mRNA Vaccines, Animals, Gene Amplification, Humans, Immunity, Innate, Immunotherapy, RNA, Messenger, Vaccines, Synthetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
